STOCK TITAN

Aptevo Therapeutics (APVO) Executive Chair exercises RSUs, withholds 406 shares for tax

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. reported that Executive Chair Marvin L. White exercised and settled restricted stock units into common stock in July and August 2026. On August 6, 2026, 1,666 RSUs granted on August 6, 2025 converted into common shares, with 406 shares withheld at $4.07 per share to satisfy tax withholding obligations. On July 17, 2026, 1 RSU from a July 17, 2024 grant vested and converted into one common share.

Positive

  • None.

Negative

  • None.
Insider White Marvin L
Role Executive Chair
Type Security Shares Price Value
Exercise Restricted Stock Unit F1, F4 1,666 $0.00 $0.00
Exercise Common Stock F1 1,666 -- --
Tax Withholding Common Stock F2 406 $4.07 $2K
Exercise Restricted Stock Unit F1, F3 1 $0.00 $0.00
Exercise Common Stock F1 1 -- --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 1,261 shares (Direct)
Footnotes (4)
  1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
  2. F2. Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.
  3. F3. On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.
  4. F4. On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant.
RSUs converted August 6, 2026 1,666 shares Restricted Stock Units granted August 6, 2025 converting into common stock
Shares withheld for taxes 406 shares Common shares withheld on August 6, 2026 to satisfy tax withholding obligations
Tax withholding price $4.0700 per share Value used for shares withheld to cover tax obligations on August 6, 2026
RSUs converted July 17, 2026 1 share Single RSU from July 17, 2024 grant converting into one common share
July 17, 2024 RSU grant (pre-split) 22,325 RSUs Grant vesting in three approximately equal annual installments beginning July 17, 2025
August 6, 2025 RSU grant (pre-split) 30,000 RSUs Grant vesting on the first anniversary of the date of grant
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax withholding obligations financial
"Represents shares withheld by Issuer to satisfy tax withholding obligations"
post-split financial
"On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs"
vesting financial
"RSUs, vesting on the first anniversary of the date of grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Executive Chair financial
"White Marvin L serves as Executive Chair of the issuer"
An executive chair is the board chairperson who also takes an active, hands-on role in company management, typically working closely with the CEO and senior team to shape strategy and major decisions. For investors it matters because this blend of oversight and operational power can accelerate strategic moves and provide steady leadership—like a coach who also calls plays—but it can also concentrate authority and create governance or succession risks if too much depends on one person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did Aptevo Therapeutics (APVO) report for Marvin L. White?

Aptevo reported that Executive Chair Marvin L. White exercised RSUs into common stock on July 17 and August 6, 2026. These transactions reflect equity compensation vesting, not open-market buying or selling, and include shares withheld to cover tax obligations.

How many Aptevo Therapeutics (APVO) shares were acquired through RSU vesting?

Marvin L. White acquired 1,667 common shares of Aptevo through RSU conversions: 1,666 shares from an August 6, 2025 grant and 1 share from a July 17, 2024 grant, each RSU converting into one share of common stock.

How many Aptevo Therapeutics (APVO) shares were withheld for taxes in this Form 4?

Aptevo withheld 406 common shares at $4.07 per share from Marvin L. White on August 6, 2026. These shares were withheld to cover tax withholding obligations arising from the vesting of restricted stock units.

Were Marvin L. White’s Aptevo (APVO) transactions open-market trades?

No. The reported activity involves RSU exercises and related tax withholding, not open-market purchases or sales. RSUs converted into common stock on a one-for-one basis as they vested according to previously granted equity awards.

What are the key RSU grants referenced in this Aptevo (APVO) Form 4?

The Form 4 references a July 17, 2024 grant of 22,325 RSUs (1 post-split) vesting in three annual installments from July 17, 2025, and an August 6, 2025 grant of 30,000 RSUs (1,666 post-split) vesting on the first anniversary of grant.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
White Marvin L

(Last)(First)(Middle)
2401 4TH AVENUE
1,050

(Street)
SEATTLE WASHINGTON 98121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Executive Chair
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/17/2026M1A(1)1D
Common Stock08/06/2026M1,666A(1)1,667D
Common Stock08/06/2026F(2)406D$4.071,261D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)07/17/2026M1 (3) (3)Common Stock1$00D
Restricted Stock Unit(1)08/06/2026M1,666 (4) (4)Common Stock1,666$00D
Explanation of Responses:
1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. Represents shares withheld by Issuer to satisfy tax withholding obligations on the vesting of RSUs.
3. On July 17, 2024, the reporting person was granted 22,325 (1 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.
4. On August 6, 2025, the reporting person was granted 30,000 (1,666 post-split) RSUs, vesting on the first anniversary of the date of grant.
/s/ SoYoung Kwon, Attorney-in-Fact08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)